# SMAD7

## Overview
SMAD7 is a gene that encodes the protein SMAD family member 7, which is a critical inhibitory regulator within the Transforming Growth Factor beta (TGF-β) signaling pathway. As an inhibitory SMAD protein, SMAD7 plays a pivotal role in modulating cellular processes such as proliferation, differentiation, and apoptosis by preventing the phosphorylation and activation of receptor-regulated SMADs (R-SMADs). The protein is characterized by its unique structure, including the MH1 and MH2 domains, with the latter being essential for its inhibitory function. SMAD7 interacts with type I receptors and recruits E3 ubiquitin ligases, such as SMURF1 and SMURF2, to facilitate receptor degradation, thereby exerting a negative feedback on TGF-β signaling. Beyond its primary role, SMAD7 is involved in crosstalk with other signaling pathways, including the EGFR and MAPK/ERK pathways, and is implicated in various diseases, including colorectal cancer and inflammatory bowel diseases (Miyazawa2016Regulation; Kavsak2000Smad7; de2020Current).

## Structure
SMAD7 is a protein that plays a critical role in the TGF-β signaling pathway. It consists of 426 amino acids and features two main domains: the MH1 and MH2 domains. The MH1 domain, although present, is not involved in DNA binding as in other SMAD proteins, due to the absence of a unique beta-hairpin motif (Hariharan2008Structure–function). The MH2 domain is crucial for its inhibitory function, facilitating interactions with type I receptors and blocking the phosphorylation of receptor-regulated SMADs (R-Smads) (Murayama2020Structural; de2020Current).

The MH2 domain of SMAD7 is characterized by a unique three-finger-like structure stabilized by hydrogen bonds, which is essential for its inhibitory activity (Murayama2020Structural). This domain also contains a basic region with key residues such as K312, K316, K401, and R409, which are vital for interaction with the TGF-β type I receptor (de2020Current). The structural flexibility of SMAD7, attributed to longer loops in the MH2 domain, enhances its ability to interact with a diverse set of receptors (Hariharan2008Structure–function).

SMAD7 lacks the C-terminal SSXS motif found in other SMAD proteins, making it not a substrate for receptor phosphorylation (Nakao1997Identification). It also recruits E3 ubiquitin ligases, such as SMURF1 and SMURF2, to promote receptor degradation (de2020Current). The protein's structure allows it to exist as a monomer in solution, despite its ability to interact with multiple partners (Murayama2020Structural).

## Function
SMAD7 is an inhibitory protein that plays a crucial role in regulating the Transforming Growth Factor beta (TGF-β) signaling pathway in healthy human cells. It functions by binding to the TGF-β type I receptor (TbRI), preventing the phosphorylation and activation of receptor-regulated SMADs (R-SMADs) such as SMAD2 and SMAD3, thereby inhibiting downstream signaling (Stolfi2013The; de2020Current). SMAD7 also recruits E3 ubiquitin ligases like SMURF1 and SMURF2 to the receptor complex, promoting ubiquitin-mediated proteasomal degradation of the receptor, which is part of a negative feedback loop to control TGF-β signaling (Kavsak2000Smad7; de2020Current).

In addition to its role in TGF-β signaling, SMAD7 is involved in crosstalk with other signaling pathways, including the EGFR and MAPK/ERK pathways, where it regulates processes such as cell proliferation, differentiation, and apoptosis (de2020Current). SMAD7's activity is regulated by various mechanisms, including post-translational modifications like ubiquitination and acetylation, which affect its stability and function (de2020Current). It is primarily active in the cytoplasm and nucleus, where it maintains cellular homeostasis by balancing signaling pathways (de2020Current).

## Clinical Significance
Mutations and alterations in the SMAD7 gene are implicated in various diseases, particularly colorectal cancer (CRC). Genetic variations such as the rs3764482 variant have been associated with increased CRC risk, especially in the Chinese population. This variant affects the TGF-β signaling pathway by inhibiting the phosphorylation of receptor-regulated SMADs, promoting cancer cell migration and proliferation (Li2017A). Another polymorphism, rs12953717, is linked to increased CRC risk, with studies showing its association with lower SMAD7 mRNA expression in colorectal tissues (Jiang2013Genetic; Zhang2013Association).

SMAD7 is also involved in inflammatory diseases. In inflammatory bowel diseases like Crohn's disease, SMAD7 is overexpressed, inhibiting TGF-β signaling and sustaining inflammation through high NF-kB activity. An oral SMAD7 antisense oligonucleotide, Mongersen, has shown effectiveness in treating Crohn's disease by targeting this pathway (Miyazawa2016Regulation).

In cancer, SMAD7 overexpression can confer resistance to TGF-β signaling, aiding tumor progression in pancreatic cancer and correlating with poor prognosis in hepatocellular carcinoma and gastric cancer (Miyazawa2016Regulation). These findings highlight the dual role of SMAD7 in both promoting and suppressing tumorigenesis, depending on the context.

## Interactions
SMAD7 is involved in various protein interactions that regulate the TGF-β signaling pathway. It acts as an adaptor protein, recruiting E3 ubiquitin ligases such as SMURF1 and SMURF2 to the TGF-β receptor complex, promoting receptor degradation through ubiquitination (Kavsak2000Smad7; de2020Current). SMAD7 interacts with Smurf2 via a PPXY sequence in its linker region, which binds to the WW domains of Smurf2, facilitating the formation of an E3 ubiquitin ligase complex (Kavsak2000Smad7).

SMAD7 also forms a ternary complex with Axin and Arkadia, where Axin enhances the interaction between Arkadia and SMAD7, promoting SMAD7 degradation through polyubiquitination (Liu2006Axin). This interaction is crucial for regulating TGF-β signaling by downregulating inhibitory Smads like SMAD7 (Liu2006Axin).

Additionally, SMAD7 interacts with the LIM protein Hic-5/Ara55, which inactivates SMAD7 through direct physical interaction (Wang2008Smad7). SMAD7's interactions extend to other signaling pathways, such as the Wnt pathway, where it interacts with β-catenin and Axin, influencing β-catenin stability and SMAD7 turnover (de2020Current). These interactions highlight SMAD7's role in modulating various cellular processes through its involvement in multiple signaling pathways.


## References


[1. (Liu2006Axin) Wei Liu, Hongliang Rui, Jifeng Wang, Shuyong Lin, Ying He, Mingliang Chen, Qinxi Li, Zhiyun Ye, Suping Zhang, Siu Chiu Chan, Ye-Guang Chen, Jiahuai Han, and Sheng-Cai Lin. Axin is a scaffold protein in tgf-β signaling that promotes degradation of smad7 by arkadia. The EMBO Journal, 25(8):1646–1658, April 2006. URL: http://dx.doi.org/10.1038/sj.emboj.7601057, doi:10.1038/sj.emboj.7601057. This article has 137 citations.](https://doi.org/10.1038/sj.emboj.7601057)

[2. (Kavsak2000Smad7) Peter Kavsak, Richele K. Rasmussen, Carrie G. Causing, Shirin Bonni, Haitao Zhu, Gerald H. Thomsen, and Jeffrey L. Wrana. Smad7 binds to smurf2 to form an e3 ubiquitin ligase that targets the tgfβ receptor for degradation. Molecular Cell, 6(6):1365–1375, December 2000. URL: http://dx.doi.org/10.1016/s1097-2765(00)00134-9, doi:10.1016/s1097-2765(00)00134-9. This article has 1075 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s1097-2765(00)00134-9)

[3. (Jiang2013Genetic) Xuejuan Jiang, J. Esteban Castelao, David Vandenberg, Angel Carracedo, Carmen M. Redondo, David V. Conti, Jesus P. Paredes Cotoré, John D. Potter, Polly A. Newcomb, Michael N. Passarelli, Mark A. Jenkins, John L. Hopper, Steven Gallinger, Loic Le Marchand, María E. Martínez, Dennis J. Ahnen, John A. Baron, Noralane M. Lindor, Robert W. Haile, and Manuela Gago-Dominguez. Genetic variations in smad7 are associated with colorectal cancer risk in the colon cancer family registry. PLoS ONE, 8(4):e60464, April 2013. URL: http://dx.doi.org/10.1371/journal.pone.0060464, doi:10.1371/journal.pone.0060464. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0060464)

[4. (Zhang2013Association) Hongtuan Zhang, Hui Ma, Yong Xu, and Liang Li. Association of smad7 rs12953717 polymorphism with cancer: a meta-analysis. PLoS ONE, 8(3):e58170, March 2013. URL: http://dx.doi.org/10.1371/journal.pone.0058170, doi:10.1371/journal.pone.0058170. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0058170)

[5. (Li2017A) Jiaoyuan Li, Li Zou, Ying Zhou, Lu Li, Ying Zhu, Yang Yang, Yajie Gong, Jiao Lou, Juntao Ke, Yi Zhang, Jianbo Tian, Danyi Zou, Xiating Peng, Jiang Chang, Jing Gong, Rong Zhong, Xiaobo Zhou, and Xiaoping Miao. A low‐frequency variant in smad7 modulates tgf‐β signaling and confers risk for colorectal cancer in chinese population. Molecular Carcinogenesis, 56(7):1798–1807, March 2017. URL: http://dx.doi.org/10.1002/mc.22637, doi:10.1002/mc.22637. This article has 39 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/mc.22637)

[6. (Wang2008Smad7) H Wang, K Song, T L Krebs, J Yang, and D Danielpour. Smad7 is inactivated through a direct physical interaction with the lim protein hic-5/ara55. Oncogene, 27(54):6791–6805, September 2008. URL: http://dx.doi.org/10.1038/onc.2008.291, doi:10.1038/onc.2008.291. This article has 44 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/onc.2008.291)

[7. (Hariharan2008Structure–function) Ramkumar Hariharan and M. Radhakrishna Pillai. Structure–function relationship of inhibitory smads: structural flexibility contributes to functional divergence. Proteins: Structure, Function, and Bioinformatics, 71(4):1853–1862, January 2008. URL: http://dx.doi.org/10.1002/prot.21869, doi:10.1002/prot.21869. This article has 18 citations.](https://doi.org/10.1002/prot.21869)

[8. (Miyazawa2016Regulation) Keiji Miyazawa and Kohei Miyazono. Regulation of tgf-β family signaling by inhibitory smads. Cold Spring Harbor Perspectives in Biology, 9(3):a022095, December 2016. URL: http://dx.doi.org/10.1101/cshperspect.a022095, doi:10.1101/cshperspect.a022095. This article has 320 citations and is from a peer-reviewed journal.](https://doi.org/10.1101/cshperspect.a022095)

[9. (Murayama2020Structural) Kazutaka Murayama, Miyuki Kato-Murayama, Yuka Itoh, Kohei Miyazono, Keiji Miyazawa, and Mikako Shirouzu. Structural basis for inhibitory effects of smad7 on tgf-β family signaling. Journal of Structural Biology, 212(3):107661, December 2020. URL: http://dx.doi.org/10.1016/j.jsb.2020.107661, doi:10.1016/j.jsb.2020.107661. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jsb.2020.107661)

[10. (Stolfi2013The) Carmine Stolfi, Irene Marafini, Veronica De Simone, Francesco Pallone, and Giovanni Monteleone. The dual role of smad7 in the control of cancer growth and metastasis. International Journal of Molecular Sciences, 14(12):23774–23790, December 2013. URL: http://dx.doi.org/10.3390/ijms141223774, doi:10.3390/ijms141223774. This article has 71 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms141223774)

[11. (Nakao1997Identification) Atsuhito Nakao, Mozhgan Afrakhte, Anita Morn, Takuya Nakayama, Jan L. Christian, Rainer Heuchel, Susumu Itoh, Masahiro Kawabata, Nils-Erik Heldin, Carl-Henrik Heldin, and Peter ten Dijke. Identification of smad7, a tgfβ-inducible antagonist of tgf-β signalling. Nature, 389(6651):631–635, October 1997. URL: http://dx.doi.org/10.1038/39369, doi:10.1038/39369. This article has 1486 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/39369)

[12. (de2020Current) Charlotte de Ceuninck van Capelle, Maureen Spit, and Peter ten Dijke. Current perspectives on inhibitory smad7 in health and disease. Critical Reviews in Biochemistry and Molecular Biology, 55(6):691–715, October 2020. URL: http://dx.doi.org/10.1080/10409238.2020.1828260, doi:10.1080/10409238.2020.1828260. This article has 39 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/10409238.2020.1828260)